Related Experiment Videos
Guillain-Barré syndrome
1Department of Neurology, UMDS, Guy's Hospital, London, UK.
Current Opinion in Neurology
|October 1, 1994
Summary
Guillain-Barré syndrome encompasses various conditions, including demyelinating and axonal neuropathies. Intravenous immunoglobulin shows promise but requires further study due to potential relapses.
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Guillain-Barré syndrome is a complex clinical entity with diverse pathological underpinnings.
- Infections, particularly Campylobacter jejuni, and anti-ganglioside antibodies are implicated in its pathogenesis.
- Miller Fisher syndrome is linked to anti-ganglioside GQ1b antibodies.
Purpose of the Study:
- To review the pathological entities comprising Guillain-Barré syndrome.
- To explore the role of Campylobacter jejuni and anti-ganglioside antibodies in axonal damage.
- To evaluate the efficacy of intravenous immunoglobulin (IVIg) compared to plasma exchange for Guillain-Barré syndrome treatment.
Main Methods:
- Review of current literature on Guillain-Barré syndrome.
- Analysis of associations between preceding infections, antibodies, and clinical outcomes.
- Comparison of treatment outcomes from controlled trials and case series.
Main Results:
- Guillain-Barré syndrome includes acute inflammatory demyelinating polyradiculoneuropathy and acute motor axonal neuropathy.
- Campylobacter jejuni and anti-ganglioside GM1 antibodies correlate with axonal damage and poor prognosis.
- Intravenous immunoglobulin demonstrated comparable efficacy to plasma exchange in one trial, but relapses warrant further investigation.
Conclusions:
- Guillain-Barré syndrome is heterogeneous, with distinct subtypes and associated pathological mechanisms.
- The role of specific antibodies in axonal damage requires further elucidation.
- While IVIg is a viable treatment, its long-term efficacy and potential for relapse necessitate ongoing research.